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THE PROBABLE MECHANISM OF STREPTOMYCIN ACTION
IN TUBERCULOSIS*
H. J. CORPER AND MAURICE L. COHN
The mechanism of streptomycin action in tuberculosis still appears
to be an open question. Although from the first suggestion of its use for
treating tuberculous man, it was taken for granted that its action was
simply that of a tuberculostatic agent in vivo, simulating the action
noted in vitro in certain culture tests under definitely established con-
ditions. There were a few enthusiasts who led one to infer that
streptomycin could kill tubercle bacilli readily and directly in vivo5 as
well as in vitro.7 Such simple action would certainly prove highly
desirable in achieving a cure for tuberculosis, but unfortunately it takes
into little account the multiple problems involved in the various re-
actions of the tubercle bacillus and the similarities upon which are based
its parasitism in the human or animal body. These mechanisms are also
far from being completely elucidated. Extreme caution is necessary to
avoid hasty deductions, if past experiences with the tubercle bacillus
and tuberculosis are used as evidence.
In a preliminary report2 in 1946, it was pointed out that:
Streptomycin properly administered and in proper dosage is capable of retard-
ing the development or growth of human tubercle bacilli both in vitro...and in
vivo. The concentration of streptomycin required to retard the growth of tubercle
bacilli in vitro in good nutrient mediums can only be attained in vivo for a
brief period by any route of administration or amount of streptomycin that can
be used. There is no evidence available . . . to indicate that streptomycin enters
the important organs in appreciable amount for any significant time, although
it is present in the blood, or that it accumulates in these organs. There is no
evidence that tubercle bacilli adsorb or absorb streptomycin or that it accumu-
lates in these bacilli in vitro or in vivo.
In 1947 it was further noted4 that: "Streptomycin cannot be con-
sidered a cure for tuberculosis in man at present since it is incapable of
destroying virulent human tubercle bacilli or of completely retarding
their development in vivo under the best experimental conditions. In
experimental virulent infection, streptomycin is capable of retarding
tuberculosis, but it is incapable of completely negating a lethal issue
from such infection." Still later, itwas recorded3 that "Streptomycin does
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not appear to act in tuberculosis as a simple chemotherapeutic retardant,
as it does in the testtube, but that there is a threshold of remote sustained
action. Wheninitiatedminimally, theeffectpersists for some time; above
the maximum threshold effect, it is needless to continue forcing treat-
ment, since the benefit derived does not exceed that of the established
maximum."
With a view to extend the information on the mechanisms of action
of streptomycin in tuberculosis further, a series of controlled in vitro and
in vivo tests with tubercle bacilli in various mediums as well as con-
trolled animal tests were performed and will be presented briefly.
In vitro studies
It has been shown that streptomycin definitely has its limitations
even as a retardant to the growth of human tubercle bacilli, particularly
when planted on a good nutrient medium and especially one containing
egg. Even slight modifications in simple mediums or in variation of
amount of plants serve to change markedly the unit-retarding values
of streptomycin for tubercle bacilli. To note whether streptomycin is
destroyed, adsorbed, or inactivated in egg mediums, which might
account for its lack of action on the growth of tubercle bacilli in these
mediums, varying amounts of streptomycin were added to egg-white
and egg-yolk before coagulation sterilization. Then known weights of
the medium were tested for streptomycin content against a known
acid-fast saprophyte (Day) sensitive to small amounts (1 unit) of
streptomycin on glycerol agar and glycerol broth mediums. These med-
iums disclosed a full value of free streptomycin action, and this was
readily diffusible and soluble in the simple test mediums (Fig. 1).
In order to determine the effect of different amounts of
streptomycin in vitro at 370 C. upon a virulent strain of human tubercle
bacilli (#4008), both in regard toviability and resistance development,
an experiment was performed and is presented briefly in Table 1.
The findings recorded in Table 1 indicate that up to 1000 units of
streptomycin brought in contact with virulent human tubercle bacilli
do not destroy the bacilli during exposure at 370 C. in a buffered non-
nutrient simple synthetic non-protein medium for four weeks. It is
evident, however, that in the direct transfer, especially with 100 units
per cc. and 1000 units per cc. of streptomycin, sufficient is carried onto
the yolk nutrient medium to retard the growth; but when diluted to
1:1000 (0.001 mg.) growth occurs without apparent retardation. It is
also apparent that such exposure to 1000 units of streptomycin per cc.
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at 370 C. does not alter the bacilli sufficiently to change their growth
ability either on nutrient broth medium or on yolk medium containing
various concentrations of streptomycin up to 1000 units per cc. There
is no evidence from this study that the original bacilli develop resistance
to streptomycin or that they contain a resistant variant-making it
appear likely that resistance development to streptomycin is a factor
of multiplication of the bacilli and inherent in the progeny and adapta-
tion rather than a change in the original bacilli themselves.
Infection experiments with guinea-pigs, in elaboration of the above
culture tests, also disclosed that exposure of virulent human tubercle
bacilli in non-nutrient Wong's medium kept at 370 C. and containing
amounts of streptomycin up to 1000 units per cc. for a period as long
as one month did not produce any change in the bacilli. This indicates
that the resistance of the bacilli has not been altered sufficiently to
prevent streptomycin treatment (using 5000 to 25,000 units of
TABLE 2
EFFECT OF STREPTOMYCIN TREATMENT OF GUINEA-PIGS INFECTED WITH STREP- TOMYCIN NON-RESISTANT AND RESISTANT VIRULENT HUMAN TUBERCLE BACILLI (No. 4008) AFTER PROLONGED CONTACT WITH STREPTOMYCIN
Amount of
streptomycin Days after infection with
Type of tubercle bacilli used for 1 mg. bacilli intravenously
and in vitro treatment daily treatment when guinea-pigs died
of guinea-pigs
19, 23, 25, 27, and 27
#4008 None Average, 24 days
Streptomycin resistant 18, 21, 27, 32, and 32
#4008 None Average, 26 days
Streptomycin resistant 18, 20, 25, 28, and 28
#4008 25,000 Units Average, 24 days
#4008
Contact with 1000 units 26, 29, 29, 32, and 35
streptomycin for 1 month None Average, 30 days*
at 370 C.
#4008
Contact with 1000 units 65, 108, 112, 132, and 158
streptomycin for 1 month 5,000 Units Average, 115 dayst
at 370 C.
* The 1 month's residence in the incubator showed a slight reduction of viable
bacilli, which is borne out in culture dilution test.
tSome of these guinea-pigs revealed no evident macroscopic tuberculosis, although
cultures from all the organs were distinctly positive.
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streptomycin per day) of the guinea-pigs infected with these bacilli
from showing a definite retardation of their tuberculosis. Controls in-
fected with streptomycin-resistant bacilli (resistance of the bacilli pro-
duced in vitro) showed no appreciable effect under similar streptomycin
treatment. This is shown in Table 2.
It is apparent from the results recorded in Table 2 that prolonged
contact, up to one month at 370 C., with up to 1000 units of
streptomycin per cc. does not alter appreciably the streptomycin re-
sistance of virulent human tubercle bacilli as determined by controlled
guinea-pig infection and streptomycin-treatment tests. Also streptomycin
does not affect infection in guinea-pigs with streptomycin-resistant
strains of virulent human tubercle bacilli as far as can be determined,
verifying previous observations.6'9
In view of the action in vivo of intermittent treatment with
streptomycin for retarding tuberculosis in the guinea-pig,3 it appeared
desirable to study the effect of intermittent exposure to varying amounts
of streptomycin per cc. in a simple nutrient medium (glycerol broth)
-co?yd?edaJitabe
FIG. 1
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suited both to growing tubercle bacilli and to the adequate in vitro
action of streptomycin without evident unit disturbance. In a suitably
constructed apparatus for this purpose in which the medium could be
changed from streptomycin-containing to streptomycin-free nutrient at
varying intervals, the results recorded in Table 3 were obtained with a
human tubercle bacillus.
TABLE 3
EFFECT OF INTERMITTENT EXPOSURE TO STREPTOMYCIN ON THE GROWTH OF
HUMAN TUBERCLE BACILLI
Time ofexposure Units ofstreptomycin in glycerol broth medium*
to streptomycin 0 1 10 100 10001
1 day out of 5 +t + + + 0
1 day out of 3 + + + + 0
1 day out of 2 + 0§ 0 0 0
* Glycerol broth is a simple liquid nutrient medium suited to growing heavy plants
(1 mg. or more) of human tubercle bacilli in which streptomycin will retard growth in
1 unit (or microgram) per cc.
t 0 = absence of growth, and ± = definite macroscopic growth.
I The absence of growth with the 1000 units per cc. amounts of streptomycin is
accounted for by the inability in the apparatus used to remove all trace of streptomycin
completely in the streptomycin-free period, since the nutrient medium for such culture
period was found to contain by analysis in excess of 1 to 5 units of streptomycin per cc.
shortly after the experiment was initiated.
§ These cultures were all surface planted, and the daily disturbance of the plants
played a significant part in the absence of growth here.
The results recorded in Table 3 indicate that intermittent exposure
in vitro to streptomycin in concentrations up to 100 units per cc. in
glycerol broth medium, suited to continuing unit evaluation retardation
against the human tubercle bacillus, is without evident retardation effect
toward the growth of the bacilli if exposure to the streptomycin is less
than every other day. Therefore, unless some other mechanism is at
the basis of the remote threshold retardant action noted in the animal
(guinea-pig), the simple retardant in vitro effect of streptomycin cannot
be translated directly into in vivo action upon the growth of the tubercle
bacilli. In addition, these experiments provide further evidence that
streptomycin is not adsorbed or absorbed in active form by the tubercle
bacilli.
In vivo studies
From the in vitro studies, it would appear that mammalian tubercle
bacilli may develop resistance to streptomycin, especially under con-
ditions where growth is possible, even though retardation occurs; re-
tardation in even relatively large concentrations of streptomycin is only
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partial; and that streptomycin within reasonable limits of concentration
will not kill tubercle bacilli. In addition, in vitro retardation is con-
tingent upon the presence of streptomycin in retarding amounts under
the conditions in which retardation can actually take place. This poses
the problem of the relation of the in vitro growth of tubercle bacilli
and in vivo retardation of tuberculosis as influenced by streptomycin.
Chemical and biological studies of the persistence and excretion of
streptomycin following injection suggest that repeated administrations
are required at less than 24-hour intervals to attain a constant level of
possible active retarding amount in the body, and yet injections spaced
from 5- to 10-day intervals reveal a significant retardation of tuber-
TABLE 4
THE EFFECT OF STREPTOMYCIN TREATMENT ON THE RECOVERY OF VIRULENT HUMAN TUBERCLE BACILLI FROM THE ORGANS OF GUINEA-PIGS INFECTED INTRAVENOUSLY
Bone
Treatment given Lung Liver Spleen Kidney Brain marrow
Control #1 2* 2 2 4 4 3
50 mgs. streptomycin once
same day as infection 2 2 2 3 6 4
Control #2 2 2 2 3 3 3
25 mgs. streptomycin daily
for 3 days 2 2 2 3 6 3
Control #3 2 2 2 3 5 3
25 mgs. streptomycin daily
for 4 days 3 3 3 3 6 3
Control #4 2 2 2 3 6 3
25 mgs. streptomycin in 4
divided doses for one day 2 3 3 3 6 3
Control #5 2 3 2 3 0 3
25 mgs. streptomycin once
2 days after infection 2 3 3 3 ° 3
Control #6 2 3 2 3 0 3
25 mgs. streptomycin once
5 days after infection - 2 3 2 3_ 5 3
* All the animals were killed 4 days after the last streptomycin treatment. The
numeral indicates the number of weeks after which positive growth of the bacilli occurred
on the egg-yolk medium.
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culosis produced by infecting guinea-pigs with highly virulent mammal-
ian tubercle bacilli. From these observations, it would appear that direct
retardation of the growth of the bacilli cannot be translated into the
effects noted in vivo.
In order to elucidate further the in vivo retardation of tuberculosis
by streptomycin administration, various controlled tests were performed
as follows to aid in the solution of this problem: large doses of
streptomycin were given repeatedly to maintain a high concentration
in the blood during the early periods of intravenous infection to see if
it would affect the bacilli so far as their recovery from the organs could
be determined. The guinea-pigs were given an intravenous injection
of 1 mg. of virulent human tubercle bacilli (#4008)) and streptomycin
TABLE 5
THE RECOVERY OF AVIRULENT AND VIRULENT HUMAN TUBERCLE BACILLI FROM THE
BLOOD AFTER INTRAVENOUS INJECTION AND STREPTOMYCIN TREATMENT
Time after Results of culture of blood*
intravenous following injection of
injection Avirulent Virulent
of 1 mg. humantubercle human tubercle
bacilli bacilli bacilli No. 4008
1 hour Control 4t 5
25 mgs. streptomycin daily 4 10
1 day Control 4 4
25 mgs. streptomycin daily 4 6
3 days Control 3 7
25 mgs. streptomycin daily 4 8
1 week Control 4 6
25 mgs. streptomycin daily 6 9
2 weeks Control 6 41
25 mgs. streptomycin daily 6 0
4 weeks Control 0 Dead
25 mgs. streptomycin daily 0 0
'The blood was taken for culture each period just before the daily streptomycin
injection so that the streptomycin would not interfere with growth.
tThe numeral indicates the number of weeks after which the egg-yolk culture
became positive.
4 After 2 weeks following virulent infection, the bacilli return to the circulation in
large numbers due to generalized tuberculosis.
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by various routes, after which the organs were cultured. The findings
in typical experiments are briefed in Table 4.
The findings recorded in Table 4 indicate that brief treatment with
streptomycin in large amounts does not influence the recovery of viru-
lent human tubercle bacilli from the organs of the guinea-pig following
intravenous injection.
In order to elaborate further on the foregoing findings, the per-
sistence of the bacilli in the blood after intravenous injection of 1 mg.
was studied over a four-week interval of streptomycin treatment. For
this purpose both avirulent and virulent human tubercle bacilli were
used in gunea-pigs. The results are given briefly in Table 5.
The findings recorded in Table 5 indicate that streptomycin treat-
ment with large daily doses for one month does not influence the rate
of disappearance of either avirulent or virulent human tubercle bacilli
following intravenous injection. It is evident from the foregoing experi-
ments, summarized in Tables 4 and 5, that such effect as occurs on
tuberculosis as a result of streptomycin treatment cannot be attributed
either to a change in the persistence of the bacilli in the blood or an
alteration of the organic presence of the bacilli in viable form after
intravenous injection.
In additional experiments in which infection was produced by the
intravenous injection of 0.000,001 mg. of virulent human tubercle
bacilli, it was found that although the tuberculosis is retarded per-
ceptiblyby onemonth of intensive treatment with streptomycin (25,000
units daily) this does not destroy the tubercle bacilli and the animals
eventually die of evident and marked macroscopic tuberculosis. This
infecting dose borders on the minimum, and yet one month of intensive
treatment with streptomycin (equivalent on a proportionate weight
basis to far more than can be administered to man safely) did not
destroy the bacilli in the body.
In order to note the effect of continuous daily administration of
different amounts of streptomycin upon lethal tuberculosis produced by
the intravenous injection of 1 mg. of fine suspension of virulent human
tubercle bacilli, a series of guinea-pigs was treated until death, or up
to 250 days, with the results recorded in Table 6.
It is evident from the findings recorded in Table 6 that daily ad-
ministration of streptomycin up to 10 mg. per day for 250 days did not
prevent a lethal outcome following intravenous infection and that such
effect appeared to be graded, dependent upon the amount of strep-
tomycin used, from 1 mg. up to 10 mg. This effect could not be en-
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TABLE 6
THE EFFECT OF THE AMOUNT OF STREPTOMYCIN USED IN CONTINUOUS DAILY
TREATMENT UPON LETHAL TUBERCULOSIS
Amount of streptomycin Days after intravenous infection
used for treatment given with I mg. virulent human
subcutaneously tubercle bacilli when Tuberculosis
guinea-pigs died
19, 21, 21, 22, and 26
Controls-no treatment Average, 22 days Generalized miliary
19, 20, 21, 22, and 29
0.01 mg. daily Average, 22 days Generalized miliary
18, 18, 24, 25, and 31
0.1 mg. daily Average, 23 days Generalized miliary
70-day animal - 4,
all the others re-
1.0 mg.t daily 70, 83, 92, 92, and 114 vealed no macro-
Average, 90 days scopic tuberculosis
5.0 mg.t daily for 250 107, 115, 137, 166, and 307
days Average, 166 days 3, 2, 0, 4, 2*
10.0 mg.t daily for 250 203, 221, 226, 239, and 260
days Average, 230 days 4, 4, 3, 3, 4
* The macroscopic tuberculosis was graded either as a generalized miliary or from
O = no evident macroscopic tuberculosis, to 4 = a massive involvement of all the important
organs.
t Following subcutaneous injection of 1 mg. of streptomycin, analyses revealed a
maximum of 5 to 30 1g of streptomycin per cc. of blood for 30 minutes and its absence
in 1 hour, while 5 mg. showed 10 to 50 1Ag per cc. of blood for 2 hours and its absence
after 4 hours, and 25 mg. streptomycin subcutaneously produced 50 to 450 ,Ag up to 4
hours and total absence after 12 hours.
hanced by the use of 25 mg. of streptomycin daily even though this
approximated the maximum daily limit tolerated safely in guinea-pigs.
It is noted that some of these animals died in spite of the absence of
macroscopic tuberculosis, but tubercle bacilli could be isolated from all
the important organs. From the blood analyses for streptomycin, it is
difficult to correlate the retardant effects with the presence of
streptomycin. In experiments in which a single large dose of
streptomycin was given at various intervals after intravenous infection,
no evident effect was noted either on the time of lethal issue or amount
of tuberculosis found at death, suggesting that a single dose even at
time of infection did not injure the bacilli appreciably. If streptomycin
was given daily in large doses at weekly intervals, a pronounced effect
was discernible however, with the results that these animals given 25
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mg. daily at weekly intervals for 190 days survived for 132 days (4+
tuberculosis), 221 days (3+), 221 days (0), 232 days (4+), and
250 days (4+), average 211 days (all but one dying with evident
tuberculosis) compared with five controls that averaged 20 days with
fine miliary tuberculosis.
In view of the fact that guinea-pigs infected intravenously show
little effect on the general well-being and weight curve even with 1 mg.
of virulent human tubercle bacilli until after 10 days when a precipitous
effect becomes evident, it seemed desirable to note what effect might
be induced, at various stages of the infection, by a relatively short period
of streptomycin treatment. The results of such an experiment are briefed
in Table 7.
TABLE 7
THE PERIOD AFTER INTRAVENOUS INFECTION WHEN STREPTOMYCIN DISPLAYS MOST
RETARDATION OF TUBERCULOSIS
Time and duration of treatment with 25 mg.
streptomycin subcutaneously after infection Days after infection when guinea-pigs
with 1 mg. vsrulent human tubercle bacilli died
(#4008) itravenously
16, 21, 22, 22, & 23
Control-no treatment Average, 21 days
22, 24, 26, 28 & 28
1 Day Average, 26 days
22, 22, 23, 24, & 25
1 & 2 Days Average, 23 days
16, 22, 24, 28, & 33
1, 2, & 3 Days Average, 25 days
22, 27, 28, 30, & 37
1, 2, 3, & 4 Days Average, 29 days
25, 25, 32, 36, & 39
1, 2, 3, 4, & 5 Days Average, 31 days
23, 32, 39, 49, & 60
6, 7, 8, 9, & 10 Days Average, 41 days
34, 41, 51, 56, & 63
11, 12, 13, 14, & 15 Days Average, 49 days
26, 41, 41, 42, & 48
16, 17, 18, 19, & 20 Days Average, 40 days
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The findings in Table 7 disclose the interesting fact that treatment
with streptomycin exerts very little effect for the first five days, even
when large doses are used; but after this time, a definite beneficial effect
is noted which becomes particularly marked in the interval from the
11th to the 15th days after intravenous infection. From this it appears
likely that the direct action of the streptomycin on the bacilli should
be more evident in the early periods of infection as a preventive of
multiplication of the bacilli or their initiation of growth. However,
since the effect is more significant at the period of tubercle formation,
there appears to be a more prominent effect on tuberculosis rather than
on the tubercle bacillus per se. This effect of streptomycin is further
emphasized when considering the results of intracutaneous infection
and lesions since they can be studied from inception throughout the
period. When guinea-pigs are given suitable intracutaneous injections
of virulent human tubercle bacilli (0.01 mg.), a striking effect of the
treatment is noted with large subcutaneous daily amounts (25 mg.) of
streptomycin. A typical experiment of this type is presented in Chart 1
which depicts the composite size of and evolution of the skin lesions of
three guinea-pigs for each curve.
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CHART 1
The findings recorded in Chart 1 show that streptomycin retards
the development of the skin lesion resulting from the intracutaneous
injection of virulent tubercle bacilli and consequently tends to prevent
ulceration and hastens healing. However, when the animals are killed
after more than 100 days of streptomycin treatment, many of them
show evident tuberculosis of the draining lymphatic glands and internal
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organs, and this is particularly evident in animals when treatment is
begun after the establishment of the skin lesion (21 days after infec-
tion), in spite of the evident general retardation of the tuberculosis by
the streptomycin treatment. When viable or non-viable avirulenthuman
tubercle bacilli (in amounts of 0.1, 0.01, and 0.001 mg.) are used by
intracutaneous injection to produce the skin lesions, the effect is still
strikingly evident. Since no multiplication of the bacilli is involved
in this reaction, it suggests that the action of streptomycin does not
appear to be one of direct retardation of the growth of the bacilli in
vivo but rather an indirect action against the effect of the bacilli. This
is depicted in graph form in Chart 2 for the non-immune, non-allergic
guinea-pigs and in Chart 3 for the immune and allergic guinea-pigs.
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CHART 3
From these studies it would appear that streptomycin retards the
development of the skin lesions resulting from the intracutaneous in-
jection ofviable and non-viable avirulent human tubercle bacilli as well
as delaying their appearance. In the tuberculo-immune and tuberculo-
allergic guinea-pig, the streptomycin exerts no effect upon the time of
appearance of the reaction produced toward the injection of tubercle
bacilli, but does affect slightly the amount of reaction and size of
the final lesion produced by the tubercle bacilli in the skin of such
animals.
Large amounts of tubercle bacilli, dead or viable avirulent, produce
no distinct tuberculosis of the internal organs when given intravenously
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in fine suspension, but find expression mainly after the initial transient
reactions as a marked splenomegaly, reaching a maximum in about
two months and depending on dosage, after which resolution of the
splenomegaly occurs. In view of the foregoing fact, it appeared of in-
terest to note what effect, if any, streptomycin might exert on maximum
intravenous infections with fine suspensions of virulent human tubercle
bacilli (#4008). The results of such an experiment, which might be
considered forced scientific experimentation to gain explanatory infor-
mation if possible, are presented in Table 8.
TABLE 8
EFFECT OF INFECTION WITH 25 AND 100 MG. VIRULENT HUMAN TUBERCLE BACILLI
-4008 INTRAVENOUSLY AND TREATMENT WITH STREPTOMYCIN
Bacillary injections and treat- Days after infection when Spleen weight in grams ment with streptomycin guinea-pigs died
Controls-25 mg. 3, 11, 18, 20, & 20 0.7, 5.0, 4.0, 4.2, & 5.2
#4008 (no treatment) Average, 14 Average, 3.8
25 mg. #4008
25 mg. streptomycin Killed, 73 days 1.6, 3.0, 3.6, 4.0, & 10.0
daily Average, 4.4
100 mg. #4008 11, 13, 14, 15, & 15 2.0, 1.4, 2.5, 4.0, & 3.2
no treatment Average, 14 Average, 2.6
100 mg. #4008
10 mg. streptomycin 12, 35, 47, 60, & 79 3.4, 6.0, 4.0, 2.7, & 6.2
daily Average, 47 Average, 4.5
100 mg.t #4008
25 mg.t streptomycin 33, 113, 164, 172, & 180 1.9, 2.4, 1.1 (+++*)
daily for 138 days Average, 132 +++,* +++*
* Spleens were not weighed since they were enlarged and tuberculous. The +++
indicates a generalized gross tuberculosis of all the important organs.
t 1 to 5 milligrams of streptomycin exerts no effect upon these massive infections
intravenously with virulent human tubercle bacilli.
It is noted from the results recorded in Table 8 that streptomycin
in large amounts (25 mg. daily) exerts only a marked effect in pro-
longing the life of the guinea-pig infected intravenously with large
amounts (25 to 100 mg.) of virulent human tubercle bacilli, but
tuberculosis is markedly evident provided enough time has elapsed after
injection of the bacilli. The general impression gained from such tests
is that large numbers of bacilli per se are of little harm to the animal,
but the reaction to these bacilli appears to be the significant factor
against which streptomycin exerts an influence. The foregoing sug-
gested an elaboration of these findings, using viable avirulent human
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tubercle bacilli in large amounts in fine suspension intravenously in
place of the virulent bacilli used above. The findings are recorded in
Table 9 givingthe splenicweights, the spleenbeing the significantorgan
of deposit in the guinea-pig for intravenously injected avirulent bacilli.
TABLE 9
EFFECT OF STREPTOMYCIN ON SPLENOMEGALY PRODUCED BY AVIRULENT HUMAN TUBERCLE BACILLI
Treatmeni with Days after injection with 100 mg. Weight of spleen in










The findings recorded in Table 9 are suggestive of a pronounced
suppressive effect of streptomycin upon the splenic reaction in the
guinea-pig following the intravenous injection of large amounts (100
mg.) of fine suspensions of avirulent human tubercle bacilli.
In further extensive experiments to disclose the exact site of
streptomycin action, the reticulo-endothelial system was given consid-
eration. Briefly, this system was overloaded by using large amounts of
India ink and viable avirulent human tubercle bacilli, and then the
effect of streptomycin treatment in large amounts (25 mg. daily) was
noted. It was found that such treatment with India ink or avirulent
bacilli did not interfere with the normal lethal outcome fol-
lowing the intravenous injection of 1 mg. of virulent human tubercle
bacilli nor did it interfere in any way discernible with the retardant
effect of the streptomycin on the tuberculosis. In many experiments
to determine the effect of streptomycin on established experimental
tuberculosis, it was found that any interpretation placed on the resolu-
tion of tuberculosis was a matter of opinion entirely. Both the time
element and the vagaries of this disease, especially following virulent
subcutaneous or intracutaneous infections, lead to a variety of results
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involved in the immune and allergic phenomena and in the matter
of the variegated spread, both local and general, so that the amount of
tuberculous involvement at the start of treatment, and based on the
natural curve of resolution, could hardly be standardized. It is well
known that even after graded local infections with small, immediately
non-lethal, amounts of virulent human tubercle bacilli the variation,
both as to amount and spread of tuberculosis, is so great that any con-
trols border on the difficulties encountered with decisive human experi-
mentation in tuberculosis.8 So far as we were able to interpret, it did not
appear that resolution of tuberculosis in a satisfactorily controlled
manner was produced by streptomycin treatment, but that such effect
as might be seen was involved in partial retardation of tuberculosis
which consequently would lead to a favorable comparison when using
progressive controls for this purpose.
In order to gain a further insight into the action mechanism not
only of streptomycin but also of tuberculosis not previously discernible
without the aid of streptomycin, or other in vivo retardants, guinea-
pigs were treated with virulent infection coincidently, after, and during
immunization with avirulent and virulent human tubercle bacilli. A
summarized table is presented.
The findings recorded in Table 10 indicate that streptomycin treat-
ment in large amounts (25 mg. daily) does not interfere with develop-
ment of specific tuberculo-immunity nor with the development of
specific tuberculo-allergy or its bacillary intoxication phase.' It is of
interest scientifically, however, that in spite of the absence of macro-
scopic tuberculosis to account for the death of some of the intravenously
infected and streptomycin-treated guinea-pigs the injection of the viru-
lent human tubercle bacilli results lethally though retardation of death
has occurred. This is not to be accounted for by the existence of a
bacteremia, and the bacilli recovered from these guinea-pigs all proved
to be relatively streptomycin resistant. Another feature of scientific in-
terest is noted in the fact that when guinea-pigs are immunized by
streptomycin suppression of virulent bacillary tuberculosis and then
followed by a second intravenous injection of the same amount of
virulent human tubercle bacilli, practically all the guinea-pigs that
recovered from the bacillary allergic intoxication caused by the second
injection revealed marked (4-plus) tuberculosis of the organs at the
time of death. On the other hand, immunization of guinea-pigs with
avirulent bacilli given intravenously and during streptomycin treatment,
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TABLE 10





1 mg. virulent human
tuberde bacilli #4008
intravenously
Immunet + 1 mg. virulent
human tubercle bacilli
#4008 intravenously
Immune t + 1 mg. virulent
human tubercle bacilli
#4008 intravenously





Days after last infection when guinea-
pigs died and amount of tuberculosis
(macroscopically)
Notreatment 17, 18, 18, 19, 20, & 22
Average, 19 days
140-++++, Killed 161-0,*
25 mg. daily Killed 161-0,* 180-++,
for 150 days 188-0,* 184-++
No treatment 29, 31, 40, 42, 48, & 52
Average, 40 days
25 mg. daily Killed 160-0,* Killed 160-0,*
for 150 days 181-0," 182-0,* 215-0"
25 mg. daily
for 30 days
61-0,* 77-0," 81-0,* 83-0,"
88-0,* 97-0.*
Average, 81 days
1 mg. virulent human
tuberde bacilli #4008
intravenously followed
1 mo. later with another 25 mg. daily 24 hours,: 28, 31, 35, 38, & 42
injection of the same for 30 days Average, 35 days
amount of the
virulent bacilli_
1 mg. virulent human
tubercle bacilli #4008
intravenously followed 24 hours,: 24 hours,:
1 mo. later by another 25 mg. daily 153-++++, 172-+++,
injection of the same for 150 days 181-++++, 183-+++
amount of the virulent
bacilli§
* It was noteworthy that many guinea-pigs in this and previous experiments died
apparently as a result of the intravenous injection of the virulent tubercle bacilli but in the
absence of macroscopically discernible tuberculosis in sufficient amount to account for
death. Most of these occurred afterprolonged treatment or after discontinuation of treatment.
tThese animals were immunized by giving subcutaneously 1 mg. of avirulent human
tubercle bacilli 1 month prior to the virulent infection intravenously with #4008.
*: For allergic death, see Corper, H. J.: Bacillary and Tuberculin Allergy and Their
Relation to Specific Tuberculosis Immunity. Yale J. Biol. & Med., 1943, 15, 378-97.
S Streptomycin treatment was without avail against reinfection with streptomycin-
resistant bacilli although the specific immunity still exerted its effect in prolonging life
against the resistant bacilli.
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followed by the intravenous infection with virulent bacilli, resulted in
predominant macroscopic non-tuberculous lethal outcomes.
Summary and conclusions
1. Streptomycin in vitro in amounts up to 1000 units per cc. pos-
sesses no tuberculocidal action within one month of contact at 370 C.
2. Streptomycin is not adsorbed or absorbed in active form by
mammalian tubercle bacilli, nor by egg-white or egg-yolk in which it
is not destroyed by heat coagulation of these materials.
3. Streptomycin in vitro appears to act only during its presence
in nutrient mediums, which does not explain the sustained retardant
action in vivo on tuberculosis.
4. Streptomycin exerts no appreciable discernible effect upon the
viability of virulent human tubercle bacilli in vivo.
5. Streptomycin retards skin tuberculosis produced by the intra-
cutaneous injection of virulent human tubercle bacilli as well as that
produced by avirulent human tubercle bacilli.
6. Streptomycin treatment, although not a complete retardant
either to tubercle bacilli in vitro or to tuberculosis in vivo, exerts a
definite effect upon the splenomegaly produced by virulent or avirulent
human tubercle bacilli.
7. Streptomycin treatment does not appear to be able to prevent
the natural development of specific tuberculo-immunity, specific
tuberculo-allergy, or bacillary allergic intoxication.
8. Streptomycin action on tuberculosis does not appear to be inter-
ferred with by loading the reticulo-endothelial system with India ink
or avirulent tubercle bacilli.
9. In retarding tuberculosis, streptomycin does not appear to pre-
vent a lethal effect from the intravenous infection with virulent human
tubercle bacilli, in spite of the fact that not enough evident macroscopic
tuberculosis is present atthe time to account for death. The streptomycin
resistance of the tubercle bacilli may play a part in this phenomenon.
10. From the evidence at present available there is a likelihood
that streptomycin does not act on tubercle bacilli per se in vivo as
retardant to their growth as it does in vitro by direct contact, but that
some intermediate mechanism accounts for its action on tuberculosis
and consequently on tubercle formation.
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FIG. 2. Persistence of streptomycin in free active form in heat-coagulated (sterile) egg yolk.
Top row: Left. Coagulated egg-yolk control (0.33 gm.).
Right. Zone of retardation with yolk containing 10,000 units/cc. using 0.1 gm. yolk for test.
Bottom row: Left. Zone of retardation with yolk containing 1000 units/cc. using 0.16 gm., and
Right. with 100 units/cc. using 0.15 gm.
Note that zones of retardation are equal to those for the same amount of streptomycin alone by
this test and there is no evidence of retention or destruction.
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to,FIG 3. Effect of streptomycin treatment on tuberculous skin lesions produced by avirulent human
tubercle bacilli.
Left. Streptomycin (25 mg. per day) treated animal.
Right. Control, untreated.
Site 1 received intracutaneously 0.1 mg. of bacilli.
Site 2 received intracutaneously 0.01 mg. of bacilli.
Site 3 received intracutaneously 0.001 mg. of bacilli.
Note definite retardation in development of tuberculous skin lesion at 20 days after intracutaneous
injection and daily treatment with streptomycin.....:..,